MedPage Today reported on a new, retrospective study involving Kyprolis over the weekend. It makes my myeloma specialist, Dr. Tricot, look pretty smart for using Kyprolis as part of my three drug post transplant consolidation therapy.
I’m always writing about a new myeloma hero that I’ve met–or someone that we’ve lost. Sounds like Cure Magazine is determined to identify and recognize them. They even use the term, “myeloma hero.”
Multiple Myeloma Hero Today!
DO YOU KNOW an individual or institution that has gone above and beyond to make a difference in […]
Friday the FDA expanded it’s approval of how and when carfilzomib (Kyprolis) can be used. Trumpets sounded. I counted eleven industry news outlets that led with the story. My reaction? Big yawn.
One of my pet peeves: when celebrities don’t disclose the type of cancer that they’re battling. They could at least devulge it in their obituary. Most of the rest of us disclose it. Obviously I’ve done so much more. I’m not implying everyone needs to be as open as I am. But come on: inquiring […]
I’m part of a Cure Talk Radio broadcast in a few hours featuring Multiple Myeloma Research Foundation co-founder, Anne Quinn Young. If you can’t listen live, I’ll pass along a link so you an listen later.
I’m part of the club: experiencing side effects caused–in part–by ongoing maintenance therapy.
Monday morning my email inbox lit up. A Wall Street Journal article–both online and in the hard copy edition–about the FDA’s unprecedented approval of three anti-myeloma drugs in less than a month was featured front and center.
Euphoria over a myeloma free PET scan doesn’t make everything else OK. I’ve been struggling with post transplant side effects. Like many of you, bumps in the medical insurance road have bubbled up unexpectedly. Still plenty of drama to kick off 2016.
New checkpoint inhibitor studies combining the experimental drug, Keytruda, with Revlimid, are working in patients who have become refractory to Revlimid.
It’s hard to believe that we’re only three months away from the 3rd Annual Pat’s Myeloma Beach Party. The event is a “party” in name only; there will be 15 myeloma experts on hand to address topics that last year’s attendees and readers feel are most important to them.
Did you see the MMRF’s outline of important myeloma related news at ASH this year? Short and to the point.
Good friend and fellow myeloma survivor, Jenny Ahlstrom, is a lot better at the technical side of blogging than I am. She uses a lot of video on her site. Jenny interviewed me on Sunday at ASH. You can listen to it here:
Another exciting, new immunotherapy may be on the horizon: Keytruda
This is awesome news; another source of financial assistance for myeloma patients in need.
I promised to follow up on yesterday’s amazing news. Dr. Tricot reassures me that my tests confirm there isn’t any active myeloma left.
Looks like our highly toxic gamble to try a pair of salvage autologous stem cell transplants worked! I’m at the airport getting ready to board a plane to Atlanta on the way home, so no time to post details…
Last week I had the opportunity to interview the Senior Director of Clinical Research for Janssen Pharmaceuticals, Dr. Tahamtan Ahmadi, PhD. Janssen is the company that manufacturers newly FDA approved Darzalex (daratumumab). I promised a more detailed follow up and I’m glad to follow through.
Before I pass along important information about Takeda’s new oral proteasome inhibitor, Ninlaro (ixazomib), I wanted to share an update about how I’m doing.
Data for more than a dozen “new” myeloma drugs was presented at this week’s American Society of Hematology (ASH) meetings here in Orlando. As I described yesterday, several are hopeful crossover drugs; compounds that are already FDA approved for use against other cancers.
I’m accumulating way too much information for me to process and pass along right away. I’m still waiting on company verified combination data for Darzalex/Pomalyst/dex. I’ll also have updated stats for ongoing elotuzumab and ARRY-520 trials. In the meantime, I interviewed Dr. Thorsten Graef, the Head of Hematology and Global Medical Safety for pharmacyclics, a […]